Headquartered in Wayne, PA Fiscal year ends December NASDAQ: AVTX avalotx.com
Avalo Therapeutics is a clinical-stage biotechnology company focused on developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases. The company's lead drug candidate is abdakibart, a humanized anti-IL-1β monoclonal antibody (IgG4) that binds to interleukin-1β with high affinity and neutralizes its activity. Abdakibart is being advanced into a registrational Phase 3 program in hidradenitis suppurativa (HS), a chronic inflammatory skin condition estimated to affect 1-4% of the global population. Avalo is also developing AVTX-010, an Fc-engineered, long-acting next-generation anti-IL-1β monoclonal antibody designed to extend half-life while preserving the pharmacology and specificity of abdakibart. The company generates no product revenue and is funded through capital raises, with approximately $472.2 million in cash, cash equivalents and investments providing an expected runway into 2029. Avalo trades on the Nasdaq under the ticker AVTX and is included in the Russell 2000 and Russell 3000 indexes. Updated
Pre-Market Stock Futures: Futures are trading mixed as we get ready to kick off the first-quarter earnings season next week, and, as usual, the big money-center banks and brokerage firms will headline…
Avalo Therapeutics is a clinical-stage biotechnology company focused on developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases.
The Wall Street consensus 12-month price target for AVTX is $44.08.
